{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:11:41Z","timestamp":1792653101701,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1186\/s13052-018-0563-0","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T08:08:24Z","timestamp":1542182904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":241,"title":["Possible strategies to cross the blood\u2013brain barrier"],"prefix":"10.1186","volume":"44","author":[{"given":"Cinzia M.","family":"Bellettato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"issue":"2","key":"563_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.rdc.2013.03.004","volume":"39","author":"C Lampe","year":"2013","unstructured":"Lampe C, Bellettato CM, Karabul N, Scarpa M. Mucopolysaccharidoses and other lysosomal storage diseases. Rheum Dis Clin N Am. 2013;39(2):431\u201355.","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"563_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/mol.57.4.679","volume":"57","author":"C Rousselle","year":"2000","unstructured":"Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood\u2013brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000;57(4):679\u201386.","journal-title":"Mol Pharmacol"},{"issue":"17","key":"563_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.2174\/0929867311320170006","volume":"20","author":"G Tosi","year":"2013","unstructured":"Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, et al. Potential use of polymeric nanoparticles for drug delivery across the blood\u2013brain barrier. Curr Med Chem. 2013;20(17):2212\u201325.","journal-title":"Curr Med Chem"},{"issue":"10","key":"563_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2174\/13816128113199990463","volume":"20","author":"L Sanchez-Covarrubias","year":"2014","unstructured":"Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20(10):1422\u201349.","journal-title":"Curr Pharm Des"},{"issue":"16","key":"563_CR5","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","volume":"14","author":"DJ Begley","year":"2008","unstructured":"Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood\u2013brain barrier. Curr Pharm Des. 2008;14(16):1566\u201380.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"563_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood\u2013brain barrier. Neurobiol Dis. 2010;37(1):13\u201325.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"563_CR7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2174\/1381612043384844","volume":"10","author":"DJ Begley","year":"2004","unstructured":"Begley DJ. ABC transporters and the blood\u2013brain barrier. Curr Pharm Des. 2004;10(12):1295\u2013312.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"563_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.beem.2014.12.001","volume":"29","author":"M Scarpa","year":"2015","unstructured":"Scarpa M, Bellettato CM, Lampe C, Begley DJ. Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system. Best Pract Res Clin Endocrinol Metab. 2015;29(2):159\u201371.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.apha.2014.06.001","volume":"71","author":"JE Preston","year":"2014","unstructured":"Preston JE, Joan Abbott N, Begley DJ. Transcytosis of macromolecules at the blood\u2013brain barrier. Adv Pharmacol. 2014;71:147\u201363.","journal-title":"Adv Pharmacol"},{"issue":"1","key":"563_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/jcbfm.2012.153","volume":"33","author":"LL Muldoon","year":"2013","unstructured":"Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, et al. Immunologic privilege in the central nervous system and the blood\u2013brain barrier. J Cereb Blood Flow Metab. 2013;33(1):13\u201321.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"563_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood\u2013brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3\u201314.","journal-title":"NeuroRx"},{"issue":"6","key":"563_CR12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.2174\/138920111795542642","volume":"12","author":"PI Dickson","year":"2011","unstructured":"Dickson PI, Chen AH. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm Biotechnol. 2011;12(6):946\u201355.","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"563_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182\u20138.","journal-title":"N Engl J Med"},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.expneurol.2015.11.013","volume":"278","author":"B King","year":"2016","unstructured":"King B, Setford ML, Hassiotis S, Trim PJ, Duplock S, Tucker JN, et al. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder. Exp Neurol. 2016;278:11\u201321.","journal-title":"Exp Neurol"},{"issue":"3","key":"563_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, et al. A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016;118(3):198\u2013205.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"563_CR16","first-page":"630","volume":"13","author":"NC Sorrentino","year":"2016","unstructured":"Sorrentino NC, Fraldi A. Brain targeting in MPS-IIIA. Pediatr Endocrinol Rev. 2016;13(Suppl 1):630\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"563_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, et al. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18(1):73\u201381.","journal-title":"Genet Med"},{"key":"563_CR18","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S61288","volume":"9","author":"C-T Lu","year":"2014","unstructured":"Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Intl J Nanomed. 2014;9:2241\u201357.","journal-title":"Intl J Nanomed"},{"key":"563_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4137\/PMC.S13384","volume":"6","author":"JL Mikitsh","year":"2014","unstructured":"Mikitsh JL, Chacko AM. Pathways for small molecule delivery to the central nervous system across the blood\u2013brain barrier. Perspect Medicin Chem. 2014;6:11\u201324.","journal-title":"Perspect Medicin Chem"},{"issue":"2","key":"563_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1254\/jjp.87.97","volume":"87","author":"WM Pardridge","year":"2001","unstructured":"Pardridge WM. Brain drug targeting and gene technologies. Jpn J Pharmacol. 2001;87(2):97\u2013103.","journal-title":"Jpn J Pharmacol"},{"issue":"2","key":"563_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/17425247.2014.952627","volume":"12","author":"WM Pardridge","year":"2015","unstructured":"Pardridge WM. Blood\u2013brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207\u201322.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"563_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrd725","volume":"1","author":"WM Pardridge","year":"2002","unstructured":"Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov. 2002;1(2):131\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/B978-0-12-396962-0.00011-2","volume":"503","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood\u2013brain barrier. Methods Enzymol. 2012;503:269\u201392.","journal-title":"Methods Enzymol"},{"issue":"9","key":"563_CR24","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"DS Hersh","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des. 2016;22(9):1177\u201393.","journal-title":"Curr Pharm Des"},{"key":"563_CR25","first-page":"71","volume-title":"The blood brain barrier (BBB). Topics in medicinal chemistry","author":"A Grabrucker","year":"2014","unstructured":"Grabrucker A, Chhabra R, Belletti D, Forni F, Vandelli M, Ruozi B, et al. Nanoparticles as blood\u2013brain barrier permeable cns targeted drug delivery systems. In: Fricker G, Ott M, Mahringer A, editors. The blood brain barrier (BBB). Topics in medicinal chemistry, vol. 10. Berlin: Springer Heidelberg; 2014. p. 71\u201389."},{"issue":"2","key":"563_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","volume":"9","author":"S Barua","year":"2014","unstructured":"Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today. 2014;9(2):223\u201343.","journal-title":"Nano Today"},{"issue":"3","key":"563_CR27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11095-014-1508-y","volume":"32","author":"FQ Mayer","year":"2015","unstructured":"Mayer FQ, Adorne MD, Bender EA, de Carvalho TG, Dilda AC, Beck RC, et al. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Pharm Res. 2015;32(3):941\u201354.","journal-title":"Pharm Res"},{"issue":"7","key":"563_CR28","first-page":"549","volume":"68","author":"A M\u00fchlstein","year":"2013","unstructured":"M\u00fchlstein A, Gelperina S, Kreuter J. Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI. Pharmazie. 2013;68(7):549\u201354.","journal-title":"Pharmazie"},{"key":"563_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jconrel.2013.11.023","volume":"174","author":"A Vilella","year":"2014","unstructured":"Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, et al. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. J Control Release. 2014;174:195\u2013201.","journal-title":"J Control Release"},{"issue":"2","key":"563_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/pharmaceutics7020074","volume":"7","author":"A Vilella","year":"2015","unstructured":"Vilella A, Ruozi B, Belletti D, Pederzoli F, Galliani M, Semeghini V, et al. Endocytosis of nanomedicines: the case of glycopeptide engineered PLGA nanoparticles. Pharmaceutics. 2015;7(2):74\u201389.","journal-title":"Pharmaceutics"},{"issue":"5","key":"563_CR31","doi-asserted-by":"publisher","first-page":"e0156452","DOI":"10.1371\/journal.pone.0156452","volume":"11","author":"M Salvalaio","year":"2016","unstructured":"Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS One. 2016;11(5):e0156452.","journal-title":"PLoS One"},{"issue":"7","key":"563_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1651-2227.2012.02674.x","volume":"101","author":"R Tomanin","year":"2012","unstructured":"Tomanin R, Zanetti A, Zaccariotto E, D'Avanzo F, Bellettato CM, Scarpa M. Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. Acta Paediatr. 2012;101(7):692\u2013701.","journal-title":"Acta Paediatr"},{"issue":"2","key":"563_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/17425247.2015.966682","volume":"12","author":"DA Wolf","year":"2015","unstructured":"Wolf DA, Banerjee S, Hackett PB, Whitley CB, McIvor RS, Low WC. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Exp Opin Drug Deliv. 2015;12(2):283\u201396.","journal-title":"Exp Opin Drug Deliv"},{"issue":"5","key":"563_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.gt.3301869","volume":"10","author":"Y Kamata","year":"2003","unstructured":"Kamata Y, Tanabe A, Kanaji A, Kosuga M, Fukuhara Y, Li XK, et al. Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther. 2003;10(5):406\u201314.","journal-title":"Gene Ther"},{"issue":"457","key":"563_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1651-2227.2008.00660.x","volume":"97","author":"MS Sands","year":"2008","unstructured":"Sands MS, Haskins ME. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl. 2008;97(457):22\u20137.","journal-title":"Acta Paediatr Suppl"},{"issue":"6","key":"563_CR36","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2174\/138920111795542679","volume":"12","author":"D Pan","year":"2011","unstructured":"Pan D. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses. Curr Pharm Biotechnol. 2011;12(6):884\u201396.","journal-title":"Curr Pharm Biotechnol"},{"issue":"7","key":"563_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27(7):478\u201396.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"563_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/10611869808997870","volume":"5","author":"S Mathison","year":"1998","unstructured":"Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998;5(6):415\u201341.","journal-title":"J Drug Target"},{"issue":"7","key":"563_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/hum.2017.187","volume":"28","author":"LR Belur","year":"2017","unstructured":"Belur LR, Temme A, Podetz-Pedersen KM, Riedl M, Vulchanova L, Robinson N, et al. Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum Gene Ther. 2017;28(7):576\u201387.","journal-title":"Hum Gene Ther"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-018-0563-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:19:48Z","timestamp":1573845588000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-018-0563-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":39,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1186\/s13052-018-0563-0","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"16 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"131"}}